SAN DIEGO & BOSTON--(BUSINESS WIRE)--Voro Therapeutics, a biotechnology company developing tumor-activated biologics designed to improve the therapeutic index of immune therapies, and Alloy Therapeutics, a biotechnology ecosystem company dedicated to empowering the global biologics community, today announced a strategic research collaboration focused on the discovery and development of next-generation masked T-cell engager (TCE) therapeutics. The collaboration combines Voro's proprietary tumor-